European equities are rapidly erasing much of the outperformance gap that had favored U.S. large-caps since the AI-driven rally in American stocks began. The region's benchmark has posted one of its stronger runs in months as analyst revisions and softer expectations for Federal Reserve tightening change the allocation calculus for global investors.
Europe narrows the one-year lead
As of Thursday’s market open the STOXX 600 has delivered a 20.02% return over the last 12 months, marginally ahead of the S&P 500’s 19.82% one-year gain. That convergence would have been difficult to foresee six months ago, when consensus positioning favored U.S. equities. The short-term picture is even more compelling: over the past three months the STOXX 600 climbed 8.13%, roughly double the S&P 500’s 4.09% advance over the same period.
| Index | YTD | 1-Year | 3-Month |
|---|---|---|---|
| S&P 500 | +12.65% | +19.82% | +4.09% |
| STOXX 600 | +11.62% | +20.02% | +8.13% |
| DAX | +8.02% | +9.42% | +9.64% |
| CAC 40 | +7.04% | +11.46% | +8.63% |
| FTSE 100 | +8.83% | +17.92% | +4.67% |
The earnings revision driver
Underlying the recent price action is an unusually broad pattern of positive earnings revisions among European large-cap companies. A screen of firms with market capitalizations above 5 billion shows analysts raising EPS expectations at a pace not commonly observed in recent years, and those upward revisions are intersecting with valuations that remain meaningfully below U.S. peers.
Specific large-cap examples illustrate the dynamic. TotalEnergies exchanges hands at roughly 8.0x forward earnings while consensus projects EPS growth of 85.7% and a fair-value upside of 28.4%. The energy major closed Thursday at 75.18 and has risen 39% year-to-date, yet it still appears undervalued versus analyst targets.
In pharmaceuticals, mid-cap Ipsen sits at about 10.4x forward earnings with an expected EPS increase of 192.1% and a 34.6% fair-value upside. The stock trades near 155 and has rallied 32.1% so far this year, but the revision momentum suggests further potential.
There are also names where sentiment has lagged fundamentals. Alstom, trading at 16.23 and roughly 9.5x forward earnings, is down 35.6% year-to-date despite projected EPS growth of 191.1% and a roughly 60.5% discount to fair-value estimates. Such cases highlight where improving analyst forecasts may precede sharp re-ratings if execution follows.
London: deep discounts and mixed signals
UK-listed companies present some of the widest valuation dislocations. BP trades near 7.1x forward earnings, a low multiple among large integrated oil companies, and shows a 37.3% fair-value upside in consensus estimates. The stock is at 522 pence and has advanced 25.7% this year.
Commodities trader and miner Glencore is priced at about 12.2x forward earnings with a very large projected EPS step (1,957%) and 13.5% upside, and it has surged 42.5% year-to-date. The London Stock Exchange Group, despite being down 1.1% year-to-date, screens at roughly 18.5x forward with projected earnings growth of 104% and a 21.9% fair-value upside, positioning it as a quality compounder trading below the revision trajectory.
Germanys re-rating in industrials and financials
Germanys DAX has been among the fastest movers recently, gaining 9.64% in the last three months. Key constituents illustrate why analysts are reassessing the market. Bayer now trades at about 11.3x forward earnings with projected EPS growth of 219.6%; the company has climbed 30.1% year-to-date to 48.27 and is being viewed more as a turnaround candidate than a permanent value write-down.
European banks are part of the story as well. Commerzbank trades near 12.5x forward earnings with projected EPS growth of 52.1% and a 10.6% upside, evidence of a broader re-rating among financials that have benefited from expectations of higher yields across parts of the region.
Macro catalysts behind the move
The earnings revision cycle has coincided with a changing macro backdrop. U.S. consumer price index data for July showed headline inflation rising 0.1% month-over-month and core inflation at 2.5% year-over-year. Those prints reduced market-implied odds of a September Fed rate hike from roughly 67% to about 40% in the sessions cited, easing pressure on the dollar and providing relief for European exporters and companies exposed to emerging markets.
At the same time, the UK economy expanded by 0.4% in the second quarter, matching consensus, a datapoint that contributes to the narrative of stabilizing growth in the region.
Interpretation and unanswered questions
The current confluence - accelerating positive earnings revisions and lingering valuation discounts relative to U.S. peers - is uncommon. European large-caps still trade at meaningful discounts on metrics such as price-to-earnings, EV/EBITDA, and free cash flow yield, even as analysts lift forecasts. Whether this represents a sustained rotation into European equities or a shorter-term mean-reversion remains unresolved.
The facts are clear: the valuation gap exists, the revision momentum is measurable, and macro developments have become more supportive. What is not yet resolved is whether corporate execution across Europe can match the expectations now being priced into consensus estimates.
Summary
Positive earnings revisions across European large-caps, combined with softened expectations for near-term Fed tightening, have brought the STOXX 600 to parity and even slightly ahead of the S&P 500 on a one-year basis. Valuation gaps versus U.S. peers remain significant, and specific companies across energy, pharmaceuticals, industrials, and financials illustrate why analysts are upgrading forecasts. The persistence of this trend depends on whether companies can deliver on the revised expectations.
- Key points:
- European benchmarks have narrowed the one-year performance gap with the S&P 500, led by a strong three-month run in the STOXX 600.
- Analyst upgrades are broad-based among large-caps, with notable projected EPS growth and measured valuation discounts relative to U.S. peers; sectors affected include energy, pharmaceuticals, industrials, and financials.
- A softer near-term Fed outlook and stabilizing UK growth have acted as macro tailwinds for Europes equity revision cycle.
- Risks and uncertainties:
- Execution risk - European companies must deliver against raised analyst forecasts for the re-rating to persist; this affects industrial, energy, and pharmaceutical sectors.
- Macro sensitivity - renewed U.S. inflation strength or a shift back toward tighter Fed expectations could reverse recent currency and capital flow dynamics, impacting exporters and financials.
- Sentiment divergence - names trading at deep discounts despite raised EPS projections (for example, companies with significant YTD declines) could remain under pressure if investor sentiment does not improve.